drugset / Trial / NCT05205070
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
Timeline
- Start
- 2021-12-22
- Primary completion
- 2023-01-19
- Completion
- 2023-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosnilimab | Monoclonal antibody | — | Subcutaneous |